Jiangsu Hengrui Pharmaceuticals revenue and financials
¥47.20Change from previous close: +3.46%Absolute change: +¥1.58
In the fiscal year ended December 2025, Jiangsu Hengrui Pharmaceuticals reported revenue of ¥31.63B (+13.02% year over year). Net income was ¥7.71B, a net margin of 24.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.02%
- 2025 vs 2024
- Net income growth
- +21.69%
- 2025 vs 2024
- Net margin
- 24.4%
- 2024: 22.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | 69,867 | 50,136 | 43,785 | 42,371 |
| Current assets | 51,490 | 35,315 | 31,287 | 30,934 |
| Cash and equivalents | 40,955 | 24,816 | 20,746 | 15,111 |
| Short-term investments | 114 | 273 | 99.0 | 2,760 |
| Inventory | 2,878 | 2,417 | 2,314 | 2,451 |
| Net property, plant and equipment | 7,908 | 6,928 | 6,629 | 6,676 |
| Other intangible assets | 6,834 | 5,030 | 3,376 | 2,201 |
| Long-term investments | 557 | 666 | 695 | 768 |
| Current liabilities | 6,369 | 3,634 | 2,554 | 3,639 |
| Accounts payable | 2,270 | 1,967 | 1,510 | 1,768 |
| Total debt | 74.2 | 110 | 75.2 | 1,360 |
| Total liabilities | 8,070 | 4,045 | 2,751 | 3,958 |
| Total equity (incl. minority) | 61,797 | 46,090 | 41,033 | 38,413 |
| Retained earnings | 40,173 | 33,866 | 28,803 | 25,520 |
| Minority interest | 525 | 570 | 567 | 589 |